Loading...

TRDA ENTRADA THERAPEUTICS INC Management Changes 8-K Filing

NTRD

TRD

ENTRADA THERAPEUTICS INC

(TRDA)

2025 8-K

Financial Results Announced

Financial Statements

Financial Statements

Workforce Reductions

Clinical Trial Authorization

Financial Results

Clinical Trial Authorization

Financial Update

Financial Results

Financial Results

Securities Purchase Agreement

Update on ENTR-601-44

Annual Meeting and Amendmen...

Financial Results Announcement

Financial Results Announcement

Management Change

Resignations and Appointments

Update on ENTR-601-44

Financial Results Announcement

Amendment to License Agreem...

Sales Agreement

Clinical Trial Announcement

Appointment of Director

Financial Results Announcement

Clinical Trial Authorization

Resignation and Annual Meeting

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Strategic Collaboration and...

External Links:

On May 30, 2025, Entrada Therapeutics appointed Dr. Maha Radhakrishnan to its Board of Directors, expanding the board from six to seven members, effective June 1, 2025. Dr. Radhakrishnan brings extensive experience from Biogen and other healthcare companies, receiving stock options and fees for her service.

AI Assistant

ENTRADA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.